Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Caspofungin acetate
Teva B.V.
J02AX; J02AX04
Caspofungin acetate
70 milligram(s)
Pdr/Conc/Soln for Infus
Product subject to prescription which may not be renewed (A)
Other antimycotics for systemic use; caspofungin
Not marketed
2016-08-12
1 11-5-16 WA INDESIGN CS6 Body: Syntax roman/bold/ Italic 9pts Med info: 8pts Subhead: Univers 65 Bld 11pts Header: Univers 65 Bld 13pts 44410 CASPOFUNGIN 70MG POWDER FOR CONC. FOR SOL. FOR INF. 1 VIAL (GODOLLO) TEI HOSP 10-5-16 268 x 414mm WA Leafl et CUTTER GUIDE PMS PROCESS BLACK - Y Y - PACKAGE LEAFLET: INFORMATION FOR THE USER CASPOFUNGIN TEVA 70 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION CASPOFUNGIN READ ALL OF THIS LEAFL ET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leafl et. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leafl et. See Section 4. WHAT IS IN THIS LEAFL ET 1. What Caspofungin Teva is and what it is used for 2. What you need to know before you take Caspofungin Teva 3. How to take Caspofungin Teva 4. Possible side effects 5. How to store Caspofungin Teva 6. Contents of the pack and other information 1 WHAT CASPOFUNGIN TEVA IS AND WHAT IT IS USED FOR WHAT CASPOFUNGIN TEVA IS Caspofungin Teva contains a medicine called caspofungin. This belongs to a group of medicines called antifungals. WHAT CASPOFUNGIN TEVA IS USED FOR Caspofungin Teva is used to treat the following infections in children,adolescents and adults: • serious fungal infections in your tissues or organs (called ‘invasive candidiasis’). This infection is caused by fungal (yeast) cells called Candida. People who might get this type of infection include those who have just had an operation or those whose immune systems are weak. Fever and chills that do not respond to an antibiotic are the most common signs of this type of infection. • fungal infections in your nose, nasal sinuses or lungs (called ‘invasiv Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Caspofungin Teva 70 mg Powder for Concentrate for Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 70 mg caspofungin (as acetate). After reconstitution (see section 6.6), each ml of the concentrate contains 7.2 mg of caspofungin. Excipients with known effect: Each vial contains approximately 0.38 mg – 1.24 mg sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. The powder is a lyophilized white to off white colour powder, free of visible evidence of contamination. pH : 5.6 -7.0 Osmolality: approx. 275 mOsmol/Kg 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of invasive candidiasis in adult or paediatric patients. Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Caspofungin Teva should be initiated by a physician experienced in the management of invasive fungal infections. POSOLOGY _Adult patients_ A single 70 mg loading dose should be administered on Day 1, followed by 50 mg daily thereafter. In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). No dosage adjustment is necessary based on gender or race (see section 5.2). _Paediatric patients (12 months to 17 years)_ In paediatric patients (12 months to 17 years of age), dosing should be based on the patient’s body surface area (see Instructions for Use in Paediatric Patients, Mosteller 1 Formula). For all indications, a single Read the complete document